Skip to main content
SpringerLink
Log in
Book cover

Cancer Epigenetics pp 333–354Cite as

Cancer-Associated Infectious Agents and Epigenetic Regulation

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1238))

Abstract

Infectious agents are one of the factors which contribute to cancer development. Few examples include human papilloma virus in cervical cancer, hepatitis virus in hepatocellular carcinoma, herpes virus in Kaposi’s sarcoma, Epstein-Barr virus in nasopharyngeal carcinoma, human T-cell lymphotropic virus type-1 (HTLV-1) in T-cell leukemia and lymphoma, Helicobacter pylori in gastric cancer. These agents cause genomic instability in the host and most of them affect host immune system. Infectious agents may integrate in the host genome although their sit of integration is not fixed. Expression of some infectious agents involves epigenetic regulation by DNA methylation, histone modification, miRNA level alteration, and chromatin condensation. This chapter provides examples where epigenetic regulation has been reported in cancer-associated infectious agents. Epigenetic inhibitors and their potential in cancer control and treatment are also discussed.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

Abbreviations

ATLL:

Adult T-cell Leukemia/Lymphoma

BL:

Burkitt’s Lymphoma

EBV:

Epstein-Barr Virus

EBVaGC:

EBV-associated Gastric Carcinoma

H. pylori :

Helicobacter pylori

HBV:

Hepatitis B Virus

HCC:

Hepatocellular Carcinoma

HCV:

Hepatitis C Virus

HIV-1:

Human Immunodeficiency Virus type 1

HL:

Hodgkin Lymphoma

HTLV-1:

Human T-Lymphotropic Virus type 1

IARC:

International Agency for Cancer Research

NPC:

Nasopharyngeal Carcinoma

PTLD:

Post-Transplantation Lymphoproliferative Disease

References

  1. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Traub N, Roizman B (2004) Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 14(6):453–471. doi:10.1016/j.semcancer.2004.06.009

    CAS  PubMed  Google Scholar 

  2. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13(6):607–615. doi:10.1016/S1470-2045(12)70137-7

    PubMed  Google Scholar 

  3. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–3044. doi:10.1002/ijc.21731

    CAS  PubMed  Google Scholar 

  4. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM (2010) The global burden of cancer: priorities for prevention. Carcino-genesis 31(1):100–110. doi:10.1093/carcin/bgp263

    CAS  Google Scholar 

  5. Min DI, Burke PA, Lewis WD, Jenkins RL (1992) Acute hepatic failure associated with oral minocycline: a case report. Pharmaco-therapy 12(1):68–71

    CAS  Google Scholar 

  6. Chao A, Huang HJ, Lai CH (2012) Human papillomavirus research on the prevention, diagnosis, and prognosis of cervical cancer in Taiwan. Chang Gung Med J 35(4):297–308

    PubMed  Google Scholar 

  7. Stanley M (2008) Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 20(6):388–394. doi:10.1016/j.clon.2008.04.006

    CAS  Google Scholar 

  8. Darus CJ, Mueller JJ (2013) Development and impact of human papillomavirus vaccines. Clin Obstet Gynecol 56(1):10–16. doi:10.1097/GRF.0b013e31827af770

    PubMed  Google Scholar 

  9. Burk RD, Harari A, Chen Z (2013) Human papillomavirus genome variants. Virology 445(1–2):232–243. doi:10.1016/j.virol.2013.07.018

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Sabol I, Matovina M, Si-Mohamed A, Grce M (2012) Characterization and whole genome analysis of human papillomavirus type 16 e1-1374^63nt variants. PLoS One 7(7):e41045. doi:10.1371/journal.pone.004104510.1371/journal.pone.0041045

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Chaturvedi AK (2010) Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 46(4 Suppl):S20–S26. doi:10.1016/j.jadohealth.2010.01.016

    PubMed  Google Scholar 

  12. McLaughlin-Drubin ME, Meyers J, Munger K (2012) Cancer associated human papillomaviruses. Curr Opin Virol 2(4):459–466. doi:10.1016/j.coviro.2012.05.004

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Burd EM (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16(1):1–17

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Kitchener HC, Denton K, Soldan K, Crosbie EJ (2013) Developing role of HPV in cervical cancer prevention. BMJ 347:f4781. doi:10.1136/bmj.f4781

    PubMed  Google Scholar 

  15. Pimenta JM, Galindo C, Jenkins D, Taylor SM (2013) Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer 13:553. doi:10.1186/1471-2407-13-553

    PubMed Central  PubMed  Google Scholar 

  16. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S (2012) Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12–F23. doi:10.1016/j.vaccine.2012.07.055

    PubMed  Google Scholar 

  17. Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107(2 Suppl 1):S2–S5. doi:10.1016/j.ygyno.2007.07.067

    CAS  PubMed  Google Scholar 

  18. Gillison ML, Chaturvedi AK, Lowy DR (2008) HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113(10 Suppl):3036–3046. doi:10.1002/cncr.23764

    PubMed  Google Scholar 

  19. Gupta S, Kerkar RA, Dikshit R, Badwe RA (2013) Is human papillomavirus vaccination likely to be a useful strategy in India? S Asn J Cancer 2(4):193–197. doi:10.4103/2278-330X.119887

    Google Scholar 

  20. Schiller JT, Castellsague X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5):F123–F138. doi:10.1016/j.vaccine.2012.04.108

    CAS  PubMed  Google Scholar 

  21. Ylitalo KR, Lee H, Mehta NK (2013) Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public Health 103(1):164–169. doi:10.2105/AJPH.2011.300600

    PubMed  Google Scholar 

  22. Yu MC, Yuan JM (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12(6):421–429

    PubMed  Google Scholar 

  23. Chang ET, Adami HO (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1765–1777. doi:10.1158/1055-9965.EPI-06-0353

    CAS  PubMed  Google Scholar 

  24. Chan AT, Teo PM, Huang DP (2004) Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 31(6):794–801

    PubMed  Google Scholar 

  25. Thompson MP, Kurzrock R (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10(3):803–821

    CAS  PubMed  Google Scholar 

  26. Subramaniam K, Cherian M, Jain S, Latimer M, Corbett M, D’Rozario J, Pavli P (2013) Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications. Intern Med J 43(12):1339–1342. doi:10.1111/imj.12287

    CAS  PubMed  Google Scholar 

  27. Lin JC, Chen KY, Wang WY, Jan JS, Liang WM, Tsai CS, Wei YH (2001) Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol 19(10):2607–2615

    CAS  PubMed  Google Scholar 

  28. Wei WI, Sham JS (2005) Nasopharyngeal carcinoma. Lancet 365(9476):2041–2054. doi:10.1016/S0140-6736(05)66698-6

    PubMed  Google Scholar 

  29. Lee AW, Ng WT, Chan YH, Sze H, Chan C, Lam TH (2012) The battle against nasopharyngeal cancer. Radiother Oncol 104(3):272–278. doi:10.1016/j.radonc.2012.08.001

    PubMed  Google Scholar 

  30. Xu T, Tang J, Gu M, Liu L, Wei W, Yang H (2013) Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge. Curr Oncol 20(5):e406–e419. doi:10.3747/co.20.1456

    PubMed Central  PubMed  Google Scholar 

  31. Chan SL, Ma BB (2012) Novel systemic therapeutic for nasopharyngeal carcinoma. Expert Opin Ther Targets 16(Suppl 1):S63–S68. doi:10.1517/14728222.2011.635646

    CAS  PubMed  Google Scholar 

  32. Ferrari D, Codeca C, Bertuzzi C, Broggio F, Crepaldi F, Luciani A, Floriani I, Ansarin M, Chiesa F, Alterio D, Foa P (2012) Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population. BMC Cancer 12:208. doi:10.1186/1471-2407-12-208

    PubMed Central  PubMed  Google Scholar 

  33. de Martel C, Forman D, Plummer M (2013) Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am 42(2):219–240. doi:10.1016/j.gtc.2013.01.003

    PubMed  Google Scholar 

  34. Guggenheim DE, Shah MA (2013) Gastric cancer epidemiology and risk factors. J Surg Oncol 107(3):230–236. doi:10.1002/jso.23262

    PubMed  Google Scholar 

  35. Fock KM, Ang TL (2010) Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 25(3):479–486. doi:10.1111/j.1440-1746.2009.06188.x

    CAS  PubMed  Google Scholar 

  36. Witkowska M, Smolewski P (2013) Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm 2013:523170. doi:10.1155/2013/523170

    PubMed Central  PubMed  Google Scholar 

  37. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F (2013) H. pylori infection and gastric cancer: state of the art (review). Int J Oncol 42(1):5–18. doi:10.3892/ijo.2012.1701

    CAS  PubMed  Google Scholar 

  38. Coderc E, Chevrot A, Vallee C, Godefroy D, Dupont AM, L’Huillier F, Richard O, Rousselin B (1990) Anulography. J Radiol 71(5):331–337

    CAS  PubMed  Google Scholar 

  39. Goh KL, Chan WK, Shiota S, Yamaoka Y (2011) Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 16(Suppl 1):1–9. doi:10.1111/j.1523-5378.2011.00874.x

    PubMed Central  PubMed  Google Scholar 

  40. Suzuki R, Shiota S, Yamaoka Y (2012) Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infect Genet Evol 12(2):203–213. doi:10.1016/j.meegid.2011.12.002

    PubMed Central  PubMed  Google Scholar 

  41. Yamaoka Y (2010) Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 7(11):629–641. doi:10.1038/nrgastro.2010.154

    CAS  PubMed Central  PubMed  Google Scholar 

  42. Noto JM, Peek RM Jr (2012) The Helicobacter pylori cag pathogenicity island. Methods Mol Biol 921:41–50. doi:10.1007/978-1-62703-005-2_7

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Ta LH, Hansen LM, Sause WE, Shiva O, Millstein A, Ottemann KM, Castillo AR, Solnick JV (2012) Conserved transcriptional unit organization of the cag pathogenicity island among Helicobacter pylori strains. Front Cell Inf Microbiol 2:46. doi:10.3389/fcimb.2012.00046

    Google Scholar 

  44. Wang H, Han J, Chen D, Duan X, Gao X, Wang X, Shao S (2012) Characterization of CagI in the cag pathogenicity island of Helicobacter pylori. Curr Microbiol 64(2):191–196. doi:10.1007/s00284-011-0043-x

    CAS  PubMed  Google Scholar 

  45. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D (2013) Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 24(1):16–19. doi:10.1016/j.ejim.2012.07.006

    PubMed  Google Scholar 

  46. Suzuki H, Nishizawa T, Tsugawa H, Hibi T (2012) Molecular approaches and modern clinical strategies for the management of Helicobacter pylori infection in Japan. Keio J Med 61(4):109–119

    CAS  PubMed  Google Scholar 

  47. Malfertheiner P, Selgrad M, Bornschein J (2012) Helicobacter pylori: clinical management. Curr Opin Gastroenterol 28(6):608–614. doi:10.1097/MOG.0b013e32835918a7

    CAS  PubMed  Google Scholar 

  48. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG (2006) Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 6(11):699–709. doi:10.1016/S1473-3099(06)70627-2

    CAS  PubMed  Google Scholar 

  49. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576. doi:10.1053/j.gastro.2007.04.061

    CAS  PubMed  Google Scholar 

  50. Monto A, Wright TL (2001) The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 28(5):441–449

    CAS  PubMed  Google Scholar 

  51. Hou J, Liu Z, Gu F (2005) Epidemiology and prevention of Hepatitis B virus infection. Int J Med Sci 2(1):50–57

    PubMed Central  PubMed  Google Scholar 

  52. Ravart M, Cote H (1992) Sexoanalysis: a new insight-oriented treatment approach for sexual disorders. J Sex Marital Ther 18(2):128–140. doi:10.1080/00926239208404365

    CAS  PubMed  Google Scholar 

  53. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7(8):448–458. doi:10.1038/nrgastro.2010.100

    PubMed Central  PubMed  Google Scholar 

  54. Kew MC (2010) Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol 58(4):273–277. doi:10.1016/j.patbio.2010.01.005

    CAS  PubMed  Google Scholar 

  55. Michelin A, Henderson DK (2010) Infection control guidelines for prevention of health care-associated transmission of hepatitis B and C viruses. Clin Liver Dis 14(1):119–136. doi:10.1016/j.cld.2009.11.005, ix–x

    PubMed  Google Scholar 

  56. Kuo A, Gish R (2012) Chronic hepatitis B infection. Clin Liver Dis 16(2):347–369. doi:10.1016/j.cld.2012.03.003

    PubMed  Google Scholar 

  57. Shrestha SM, Shrestha S (2012) Chronic hepatitis B in Nepal: an Asian country with low prevalence of HBV infection. Trop Gastroenterol 33(2):95–101

    PubMed  Google Scholar 

  58. Giles ML, Visvanathan K, Lewin SR, Sasadeusz J (2012) Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv 67(1):37–44. doi:10.1097/OGX.0b013e31823e464b

    PubMed  Google Scholar 

  59. Wu TW, Lin HH, Wang LY (2013) Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 57(1):37–45. doi:10.1002/hep.25988

    PubMed  Google Scholar 

  60. Popalis C, Yeung LT, Ling SC, Ng V, Roberts EA (2013) Chronic hepatitis B virus (HBV) infection in children: 25 years’ experience. J Viral Hepat 20(4):e20–e26. doi:10.1111/jvh.1201910.1111/jvh.12019

    CAS  PubMed  Google Scholar 

  61. Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75(3):347–354

    CAS  PubMed  Google Scholar 

  62. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12):1118–1127. doi:10.1056/NEJMra1001683

    CAS  PubMed  Google Scholar 

  63. Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N (2011) Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl 17(Suppl 2):S6–S13. doi:10.1002/lt.22423

    PubMed  Google Scholar 

  64. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB (2011) Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 9(11):989–994. doi:10.1016/j.cgh.2011.07.026

    CAS  PubMed Central  PubMed  Google Scholar 

  65. Lagergren J, Mattsson F, El-Serag H, Nordenstedt H (2011) Increased risk of hepatocellular carcinoma after cholecystectomy. Br J Cancer 105(1):154–156. doi:10.1038/bjc.2011.181

    CAS  PubMed Central  PubMed  Google Scholar 

  66. Marrero JA, El-Serag HB (2011) Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 53(3):1060–1061. doi:10.1002/hep.24033, author reply 1061-1062

    PubMed  Google Scholar 

  67. El-Serag HB, Davila JA (2011) Surveillance for hepatocellular carcinoma: in whom and how? Ther Adv Gastroenterol 4(1):5–10. doi:10.1177/1756283X10385964

    Google Scholar 

  68. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA (2011) Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 60(7):992–997. doi:10.1136/gut.2010.230508

    CAS  PubMed  Google Scholar 

  69. Mahoney FJ (1999) Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 12(2):351–366

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101(19):1348–1355. doi:10.1093/jnci/djp288

    CAS  PubMed  Google Scholar 

  71. Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ (2009) Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 101(14):1019–1027. doi:10.1093/jnci/djp146

    PubMed  Google Scholar 

  72. Zanetti AR, Van Damme P, Shouval D (2008) The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26(49):6266–6273. doi:10.1016/j.vaccine.2008.09.056

    PubMed  Google Scholar 

  73. Lavanchy D (2012) Viral hepatitis: global goals for vaccination. J Clin Virol 55(4):296–302. doi:10.1016/j.jcv.2012.08.022

    PubMed  Google Scholar 

  74. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ (2000) Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15(12):1356–1361

    CAS  PubMed  Google Scholar 

  75. Moormann AM, Snider CJ, Chelimo K (2011) The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr Opin Infect Dis 24(5):435–441. doi:10.1097/QCO.0b013e328349ac4f

    PubMed Central  PubMed  Google Scholar 

  76. Chattopadhyay PK, Chelimo K, Embury PB, Mulama DH, Sumba PO, Gostick E, Ladell K, Brodie TM, Vulule J, Roederer M, Moormann AM, Price DA (2013) Holoendemic malaria exposure is associated with altered Epstein-Barr virus-specific CD8(+) T-cell differentiation. J Virol 87(3):1779–1788. doi:10.1128/JVI.02158-12

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Simonetti AC, Melo JH, de Souza PR, Bruneska D, de Lima Filho JL (2009) Immunological’s host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor. Microb Infection 11(4):435–442. doi:10.1016/j.micinf.2009.01.004

    CAS  Google Scholar 

  78. Schiller JT, Lowy DR (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10(10):681–692. doi:10.1038/nrmicro2872

    CAS  PubMed  Google Scholar 

  79. Burk RD, Chen Z, Van Doorslaer K (2009) Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics 12(5–6):281–290. doi:10.1159/000214919

    PubMed Central  PubMed  Google Scholar 

  80. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1):63–73. doi:10.1038/sj.bjc.6600688

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Abdel Mageed LM, Hafez M, El-Hameed AA, Masoud AG, Elbasmy AA (2004) Contribution of hepatitis C virus and Helicobacter Pylori co-infection as possible predisposing factors in the occurrence of gastric mucosal dysplasia. J Egypt Natl Canc Inst 16(4):231–236

    PubMed  Google Scholar 

  82. Zemel R, Issachar A, Tur-Kaspa R (2011) The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 15(2):261–279. doi:10.1016/j.cld.2011.03.001, vii–x

    PubMed  Google Scholar 

  83. Cheung MC, Pantanowitz L, Dezube BJ (2005) AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10(6):412–426. doi:10.1634/theoncologist.10-6-412

    CAS  PubMed  Google Scholar 

  84. Carr ER (2013) HIV- and AIDS-associated cancers. Clin J Oncol Nurs 17(2):201–204. doi:10.1188/13.CJON.201-204

    PubMed  Google Scholar 

  85. Angeletti PC, Zhang L, Wood C (2008) The viral etiology of AIDS-associated malignancies. Adv Pharmacol 56:509–557. doi:10.1016/S1054-3589(07)56016-3

    CAS  PubMed Central  PubMed  Google Scholar 

  86. Bonnet F, Chene G (2008) Evolving epidemiology of malignancies in HIV. Curr Opin Oncol 20(5):534–540. doi:10.1097/CCO.0b013e32830a5080

    PubMed  Google Scholar 

  87. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ (2007) Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 20(3):207–218. doi:10.1111/j.1432-2277.2006.00416.x

    CAS  PubMed  Google Scholar 

  88. Dolcetti R (2007) B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 7(2):96–101. doi:10.1016/j.autrev.2007.02.012

    CAS  PubMed  Google Scholar 

  89. Pietrzak B, Mazanowska N, Ekiel AM, Durlik M, Martirosian G, Wielgos M, Kaminski P (2012) Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients: an observational study. Virol J 9:117. doi:10.1186/1743-422X-9-117

    PubMed Central  PubMed  Google Scholar 

  90. Beckebaum S, Kabar I, Cicinnati VR (2013) Hepatitis B and C in liver transplantation: new strategies to combat the enemies. Rev Med Virol 23(3):172–193. doi:10.1002/rmv.1734

    CAS  PubMed  Google Scholar 

  91. Carestiato FN, Afonso LA, Moyses N, Almeida Filho GL, Velarde LG, Cavalcanti SM (2013) An upward trend in DNA p16ink4a methylation pattern and high risk HPV infection according to the severity of the cervical lesion. Rev Inst Med Trop Sao Paulo 55(5):329–334. doi:10.1590/S0036-46652013000500006

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Poreba E, Broniarczyk JK, Gozdzicka-Jozefiak A (2011) Epigenetic mechanisms in virus-induced tumorigenesis. Clin Epigen 2(2):233–247. doi:10.1007/s13148-011-0026-6

    CAS  Google Scholar 

  93. Chaiwongkot A, Vinokurova S, Pientong C, Ekalaksananan T, Kongyingyoes B, Kleebkaow P, Chumworathayi B, Patarapadungkit N, Reuschenbach M, von Knebel Doeberitz M (2013) Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions. Int J Cancer 132(9):2087–2094. doi:10.1002/ijc.27906

    CAS  PubMed  Google Scholar 

  94. Hernandez JM, Siegel EM, Riggs B, Eschrich S, Elahi A, Qu X, Ajidahun A, Berglund A, Coppola D, Grady WM, Giuliano AR, Shibata D (2012) DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia. PLoS One 7(11):e50533. doi:10.1371/journal.pone.0050533

    CAS  PubMed Central  PubMed  Google Scholar 

  95. Spathis A, Aga E, Alepaki M, Chranioti A, Meristoudis C, Panayiotides I, Kassanos D, Karakitsos P (2011) Promoter methylation of p16(INK4A), hMLH1, and MGMT in liquid-based cervical cytology samples compared with clinicopathological findings and HPV presence. Infect Dis Obstet Gynecol 2011:927861. doi:10.1155/2011/927861

    PubMed Central  PubMed  Google Scholar 

  96. Kaur P, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, Chemin I, Herceg Z (2010) DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis 202(5):700–704. doi:10.1086/655398

    CAS  PubMed  Google Scholar 

  97. Guo Y, Li Y, Mu S, Zhang J, Yan Z (2009) Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication. J Med Virol 81(7):1177–1183. doi:10.1002/jmv.21525

    CAS  PubMed  Google Scholar 

  98. Fang S, Huang SF, Cao J, Wen YA, Zhang LP, Ren GS (2013) Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression. Clin Exp Med 13(2):127–134. doi:10.1007/s10238-012-0182-9

    CAS  PubMed  Google Scholar 

  99. Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z (2011) Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 54(4):705–715. doi:10.1016/j.jhep.2010.07.027

    CAS  PubMed  Google Scholar 

  100. Zhu R, Zhang JS, Zhu YZ, Fan J, Mao Y, Chen Q, Zhu HG (2011) HBx-induced androgen receptor expression in HBV-associated hepatocarcinoma is independent of the methylation status of its promoter. Histol Histopathol 26(1):23–35

    CAS  PubMed  Google Scholar 

  101. Caliskan M, Cusanovich DA, Ober C, Gilad Y (2011) The effects of EBV transformation on gene expression levels and methylation profiles. Hum Mol Genet 20(8):1643–1652. doi:10.1093/hmg/ddr041

    CAS  PubMed Central  PubMed  Google Scholar 

  102. Kaczkowski B, Morevati M, Rossing M, Cilius F, Norrild B (2012) A decade of global mRNA and miRNA profiling of HPV-positive cell lines and clinical specimens. Open Virol J 6:216–231. doi:10.2174/1874357901206010216

    PubMed Central  PubMed  Google Scholar 

  103. Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, Lu W, Wan X, Ma D, Xie X (2011) Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol 224(4):484–495. doi:10.1002/path.2873

    CAS  PubMed  Google Scholar 

  104. Greco D, Kivi N, Qian K, Leivonen SK, Auvinen P, Auvinen E (2011) Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 6(7):e21646. doi:10.1371/journal.pone.0021646

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA (2008) Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27(18):2575–2582. doi:10.1038/sj.onc.1210919

    CAS  PubMed Central  PubMed  Google Scholar 

  106. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3(7):e2557. doi:10.1371/journal.pone.0002557

    PubMed Central  PubMed  Google Scholar 

  107. do Kim N, Song YJ, Lee SK (2011) The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines. Exp Mol Med 43(7):401–410. doi:10.3858/emm.2011.43.7.044

    CAS  PubMed Central  Google Scholar 

  108. Johannsen E, Lambert PF (2013) Epigenetics of human papillomaviruses. Virology 445(1–2):205–212. doi:10.1016/j.virol.2013.07.016

    CAS  PubMed  Google Scholar 

  109. Byun SW, Chang YJ, Chung IS, Moss SF, Kim SS (2012) Helicobacter pylori decreases p27 expression through the delta opioid receptor-mediated inhibition of histone acetylation within the p27 promoter. Cancer Lett 326(1):96–104. doi:10.1016/j.canlet.2012.07.032

    CAS  PubMed Central  PubMed  Google Scholar 

  110. Ding SZ, Fischer W, Kaparakis-Liaskos M, Liechti G, Merrell DS, Grant PA, Ferrero RL, Crowe SE, Haas R, Hatakeyama M, Goldberg JB (2010) Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS One 5(4):e9875. doi:10.1371/journal.pone.0009875

    PubMed Central  PubMed  Google Scholar 

  111. Fehri LF, Rechner C, Janssen S, Mak TN, Holland C, Bartfeld S, Bruggemann H, Meyer TF (2009) Helicobacter pylori-induced modification of the histone H3 phosphorylation status in gastric epithelial cells reflects its impact on cell cycle regulation. Epigenetics 4(8):577–586

    CAS  PubMed  Google Scholar 

  112. Wang G, Lo LF, Maier RJ (2012) A histone-like protein of Helicobacter pylori protects DNA from stress damage and aids host colonization. DNA Repair 11(9):733–740. doi:10.1016/j.dnarep.2012.06.006

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Xia G, Schneider-Stock R, Diestel A, Habold C, Krueger S, Roessner A, Naumann M, Lendeckel U (2008) Helicobacter pylori regulates p21(WAF1) by histone H4 acetylation. Biochem Biophys Res Commun 369(2):526–531. doi:10.1016/j.bbrc.2008.02.073

    CAS  PubMed  Google Scholar 

  114. Gruhne B, Kamranvar SA, Masucci MG, Sompallae R (2009) EBV and genomic instability – a new look at the role of the virus in the pathogenesis of Burkitt’s lymphoma. Semin Cancer Biol 19(6):394–400. doi:10.1016/j.semcancer.2009.07.005

    CAS  PubMed  Google Scholar 

  115. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison ML (2014) Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24(2):185–199. doi:10.1101/gr.164806.113

    CAS  PubMed Central  PubMed  Google Scholar 

  116. Androphy EJ (2013) Genomic instability: Ada3 and HPV E6-acetyltransferase connections? Cell Cycle 12(1):13. doi:10.4161/cc.23172

    CAS  PubMed Central  PubMed  Google Scholar 

  117. Richards KL, Zhang B, Baggerly KA, Colella S, Lang JC, Schuller DE, Krahe R (2009) Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One 4(3):e4941. doi:10.1371/journal.pone.0004941

    PubMed Central  PubMed  Google Scholar 

  118. Shen J, Wang S, Zhang YJ, Wu HC, Kibriya MG, Jasmine F, Ahsan H, Wu DP, Siegel AB, Remotti H, Santella RM (2013) Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics 8(1):34–43. doi:10.4161/epi.23062

    CAS  PubMed Central  PubMed  Google Scholar 

  119. John S, Sabo PJ, Canfield TK, Lee K, Vong S, Weaver M, Wang H, Vierstra J, Reynolds AP, Thurman RE, Stamatoyannopoulos JA (2013) Genome-scale mapping of DNase I hypersensitivity. Frederick M Ausubel et al. (eds) Current protocols in molecular biology, Chapter 27: Unit 21 27. doi: 10.1002/0471142727.mb2127s103

  120. Verma M (2012) Epigenome-wide association studies (EWAS) in cancer. Curr Genomics 13(4):308–313. doi:10.2174/138920212800793294

    CAS  PubMed Central  PubMed  Google Scholar 

  121. Rongrui L, Na H, Zongfang L, Fanpu J, Shiwen J (2014) Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis. Curr Pharm Des 20:1715

    PubMed  Google Scholar 

  122. Herceg Z, Paliwal A (2011) Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 727(3):55–61. doi:10.1016/j.mrrev.2011.04.001

    CAS  PubMed  Google Scholar 

  123. Liu WH, Yeh SH, Chen PJ (2011) Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta 1809(11–12):678–685. doi:10.1016/j.bbagrm.2011.04.008

    CAS  PubMed  Google Scholar 

  124. Huang J, Wang Y, Guo Y, Sun S (2010) Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 52(1):60–70. doi:10.1002/hep.23660

    CAS  PubMed  Google Scholar 

  125. Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, Wu Z (2013) miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 25(2):439–446. doi:10.1016/j.cellsig.2012.10.013

    CAS  PubMed  Google Scholar 

  126. Schneider BG, Piazuelo MB, Sicinschi LA, Mera R, Peng DF, Roa JC, Romero-Gallo J, Delgado AG, de Sablet T, Bravo LE, Wilson KT, El-Rifai W, Peek RM Jr, Correa P (2013) Virulence of infecting Helicobacter pylori strains and intensity of mononuclear cell infiltration are associated with levels of DNA hypermethylation in gastric mucosae. Epigenetics 8(11):1153–1161. doi:10.4161/epi.26072

    CAS  PubMed Central  PubMed  Google Scholar 

  127. Hong SJ, Lee HJ, Oh JH, Jung SH, Min KO, Choi SW, Rhyu MG (2013) Age-related methylation patterning of housekeeping genes and tissue-specific genes is distinct between the stomach antrum and body. Epigenomics 5(3):283–299. doi:10.2217/epi.13.17

    CAS  PubMed  Google Scholar 

  128. Di Mario S, Basevi V, Borsari S, Balduzzi S, Magrini N (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine. Lancet Oncol 13(2):e50. doi:10.1016/S1470-2045(12)70054-2, author reply e50

    PubMed  Google Scholar 

  129. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Markowitz LE, Group H-IW (2012) The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control 23(2):281–288. doi:10.1007/s10552-011-9877-6

    PubMed  Google Scholar 

  130. Wieland U, Stuecker M, Kreuter A (2012) HPV vaccine against anal intraepithelial neoplasia. N Engl J Med 366(4):378. doi:10.1056/NEJMc1113860#SA1, author reply 378-379

    CAS  PubMed  Google Scholar 

  131. Buchmann P, Dembek C, Kuklick L, Jager C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U (2013) A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 31(8):1197–1203. doi:10.1016/j.vaccine.2012.12.074

    CAS  PubMed  Google Scholar 

  132. Zhang C, Gong L, Chen Y, Wang X, Zhu S, Li D, Pang Y, Yin Y, Liu X, Zhu N (2013) A human-derived protein SBP (HBsAg-binding protein) can bind to hepatitis B virus surface antigen (HBsAg) and enhance the immune response to hepatitis B virus (HBV) vaccine. Mol Immunol 53(1–2):60–71. doi:10.1016/j.molimm.2012.06.014

    PubMed  Google Scholar 

  133. Vanden Berghe W (2012) Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol Res 65(6):565–576. doi:10.1016/j.phrs.2012.03.007

    CAS  PubMed  Google Scholar 

  134. Wang H, Bian S, Yang CS (2011) Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 32(12):1881–1889. doi:10.1093/carcin/bgr218

    CAS  PubMed Central  PubMed  Google Scholar 

  135. Nandakumar V, Vaid M, Katiyar SK (2011) (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 32(4):537–544. doi:10.1093/carcin/bgq285

    CAS  PubMed Central  PubMed  Google Scholar 

  136. Li Y, Tollefsbol TO (2010) Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem 17(20):2141–2151

    PubMed Central  PubMed  Google Scholar 

  137. Fang M, Chen D, Yang CS (2007) Dietary polyphenols may affect DNA methylation. J Nutr 137(1 Suppl):223S–228S

    CAS  PubMed  Google Scholar 

  138. Boumber Y, Issa JP (2011) Epigenetics in cancer: what’s the future? Oncology (Williston Park) 25(3):220–226, 228

    Google Scholar 

  139. Guan Z, Zhang J, Song S, Dai D (2013) Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagn Pathol 8(1):110. doi:10.1186/1746-1596-8-110

    CAS  PubMed Central  PubMed  Google Scholar 

  140. Qu Y, Dang S, Hou P (2013) Gene methylation in gastric cancer. Int J Clin Chem 424:53–65. doi:10.1016/j.cca.2013.05.002

    CAS  Google Scholar 

  141. Liu X, Wang Q, Niu H, Yang X, Sun J, Zhang Q, Ding Y (2013) Promoter methylation of Wilms’ tumor gene on the X-chromosome in gastric cancer. J S Med Univ 33(3):318–321

    CAS  Google Scholar 

  142. Song Y, Tian Y, Zuo Y, Tu JC, Feng YF, Qu CJ (2013) Altered expression of PTCH and HHIP in gastric cancer through their gene promoter methylation: novel targets for gastric cancer. Mol Med Rep 7(4):1159–1168. doi:10.3892/mmr.2013.1333

    CAS  PubMed  Google Scholar 

  143. Chang X, Zhang S, Ma J, Li Z, Zhi Y, Chen J, Lu Y, Dai D (2013) Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens. Cell Biochem Biophys 66(1):93–101. doi:10.1007/s12013-012-9457-8

    CAS  PubMed  Google Scholar 

  144. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7(6):759–764

    CAS  PubMed  Google Scholar 

  145. Momparler RL, Cote S, Momparler LF (2013) Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). Leuk Res 37(8):980–984. doi:10.1016/j.leukres.2013.04.019

    CAS  PubMed  Google Scholar 

  146. Nebbioso A, Carafa V, Benedetti R, Altucci L (2012) Trials with ‘epigenetic’ drugs: an update. Mol Oncol 6(6):657–682. doi:10.1016/j.molonc.2012.09.004

    CAS  PubMed  Google Scholar 

  147. Wagner JM, Hackanson B, Lubbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigen 1(3–4):117–136. doi:10.1007/s13148-010-0012-4

    CAS  Google Scholar 

  148. Greenblatt SM, Nimer SD (2014) Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 28:1396. doi:10.1038/leu.2014.94

    CAS  PubMed  Google Scholar 

  149. Tinoco G, Warsch S, Gluck S, Avancha K, Montero AJ (2013) Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 4(2):117–132. doi:10.7150/jca.4925

    PubMed Central  PubMed  Google Scholar 

  150. Campbell RM, Tummino PJ (2014) Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 124(3):1419. doi:10.1172/JCI75448

    CAS  PubMed Central  Google Scholar 

  151. Treppendahl MB, Kristensen LS, Gronbaek K (2014) Predicting response to epigenetic therapy. J Clin Invest 124(1):47–55. doi:10.1172/JCI69737

    CAS  PubMed  Google Scholar 

  152. Lai HJ, Lo SJ (2005) Epigenetic methylation of TIMP-3 may play a role in HBV-associated hepatocellular carcinoma. Chang Gung Med J 28(7):453–455

    PubMed  Google Scholar 

  153. Ferrasi AC, Pinheiro NA, Rabenhorst SH, Caballero OL, Rodrigues MA, de Carvalho F, Leite CV, Ferreira MV, Barros MA, Pardini MI (2010) Helicobacter pylori and EBV in gastric carcinomas: methylation status and microsatellite instability. World J Gastroenterol 16(3):312–319

    CAS  PubMed Central  PubMed  Google Scholar 

  154. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR (2014) Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immun Res 2(1):37–49. doi:10.1158/2326-6066.CIR-13-0126

    CAS  Google Scholar 

  155. Roukos DH (2011) Novel cancer drugs based on epigenetics, miRNAs and their interactions. Epigenomics 3(6):675–678. doi:10.2217/epi.11.91

    CAS  PubMed  Google Scholar 

  156. Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA (2012) SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 31(37):4107–4116. doi:10.1038/onc.2011.577

    CAS  PubMed Central  PubMed  Google Scholar 

  157. Sun S, Han Y, Liu J, Fang Y, Tian Y, Zhou J, Ma D, Wu P (2014) Trichostatin a targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells. PLoS One 9(3):e91610. doi:10.1371/journal.pone.0091610

    PubMed Central  PubMed  Google Scholar 

  158. Gray J, Cubitt CL, Zhang S, Chiappori A (2012) Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther 13(8):614–622. doi:10.4161/cbt.19848

    CAS  PubMed Central  PubMed  Google Scholar 

  159. Wilson-Edell KA, Yevtushenko MA, Rothschild DE, Rogers AN, Benz CC (2014) mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Res Treat 144(2):287–298. doi:10.1007/s10549-014-2877-y

    CAS  PubMed  Google Scholar 

  160. Leonard SM, Perry T, Woodman CB, Kearns P (2014) Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia. PLoS One 9(1):e87475. doi:10.1371/journal.pone.0087475

    PubMed Central  PubMed  Google Scholar 

  161. Jafary H, Ahmadian S, Soleimani M (2014) Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells. Mol Biol Rep 41:3801. doi:10.1007/s11033-014-3246-y

    CAS  PubMed  Google Scholar 

  162. De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F, Francoijs KJ, Ablain J, Valente S, Castellano R, Goubard A, Collette Y, Mandoli A, Martens JH, de The H, Nebbioso A, Mai A, Stunnenberg HG, Altucci L (2014) Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res 74:2328. doi:10.1158/0008-5472.CAN-13-2568

    PubMed  Google Scholar 

  163. de la Cruz-Hernandez E, Perez-Cardenas E, Contreras-Paredes A, Cantu D, Mohar A, Lizano M, Duenas-Gonzalez A (2007) The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J 4:18. doi:10.1186/1743-422X-4-18

    PubMed Central  PubMed  Google Scholar 

  164. Xu S, Ren J, Chen HB, Zhou H, Zhang G, Liu Q, Zhang R, Jiang SW, Li J (2014) Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells. Curr Pharm Des 20:1881

    CAS  PubMed  Google Scholar 

  165. Sarkar D (2009) HDAC inhibitors and ionizing radiation: combinatorial strategy to combat lung cancer. Cancer Biol Ther 8(9):832–834

    CAS  PubMed  Google Scholar 

  166. Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L, Martinez ED (2012) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 106(1):116–125. doi:10.1038/bjc.2011.532

    CAS  PubMed Central  PubMed  Google Scholar 

  167. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden RB (2009) Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 15(2):570–577. doi:10.1158/1078-0432.CCR-08-181310.1158/1078-0432.CCR-08-1813

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgements

We are thankful to Joanne Brodsky of The Scientific Consulting Group, Inc., for reading the manuscript and providing suggestions.

Author information

Authors and Affiliations

  1. Methods and Technologies Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health (NIH), 9609 Medical Center Dr, Rockville, MD, 20850, USA

    Vidya Vedham Ph.D.

  2. Methods and Technologies Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health (NIH), Room# 4E112. 9609 Medical Center Dr, Rockville, MD, 20850, USA

    Mukesh Verma Ph.D.

Authors
  1. Vidya Vedham Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mukesh Verma Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mukesh Verma Ph.D. .

Editor information

Editors and Affiliations

  1. National Institutes of Health, Rockville, Maryland, USA

    Mukesh Verma

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Vedham, V., Verma, M. (2015). Cancer-Associated Infectious Agents and Epigenetic Regulation. In: Verma, M. (eds) Cancer Epigenetics. Methods in Molecular Biology, vol 1238. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1804-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1804-1_18

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1803-4

  • Online ISBN: 978-1-4939-1804-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation